TIVC icon

Tivic Health Systems

3.09 USD
-0.06
1.9%
At close Updated Sep 17, 3:58 PM EDT
1 day
-1.9%
5 days
5.1%
1 month
-6.65%
3 months
-18.68%
6 months
-6.36%
Year to date
-47%
1 year
-33.97%
5 years
-99.96%
10 years
-99.96%
 

About: Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body's own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions.

Employees: 7

0
Funds holding %
of 7,463 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

345,431% more capital invested

Capital invested by funds: $54 [Q1] → $187K (+$187K) [Q2]

100% more funds holding

Funds holding: 2 [Q1] → 4 (+2) [Q2]

5.12% more ownership

Funds ownership: 0% [Q1] → 5.12% (+5.12%) [Q2]

Financial journalist opinion

Neutral
Business Wire
7 days ago
Tivic Completes Verification of Entolimod™ Cell Line: First Step in Establishing CGMP Manufacturing for BLA Filing
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that it has completed verification of its Entolimod™ cell line, the first step in establishing Current Good Manufacturing Practices (CGMP) in preparation for a Biologics License Application, or BLA. Cell line verification in recombinant protein production is required because it ensures the processes used to grow cells and activate protein expression do not comp.
Tivic Completes Verification of Entolimod™ Cell Line: First Step in Establishing CGMP Manufacturing for BLA Filing
Neutral
Business Wire
28 days ago
Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new drug applications (INDs) for its lead candidate, Entolimod™. The two INDs cover the use of Entolimod to treat acute radiation syndrome, including both hematopoietic (ARS-H) and gastrointestinal (ARS-GI) sub-syndromes, and the use of Entolimod to treat advanced cancers, including as an anti-tumor a.
Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers
Neutral
Business Wire
1 month ago
Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, is proud to announce it advanced discussions with key US Government agencies through its participation in the 2025 Military Health System Research Symposium (MHSRS), held August 4-7, 2025, in Kissimmee, Florida. The MHSRS is the Department of Defense's premier scientific meeting that brings together military, academic, and industry experts to discuss medical research and innovation.
Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025
Neutral
Seeking Alpha
1 month ago
Tivic Health Systems, Inc. (TIVC) Q2 2025 Earnings Call Transcript
Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Jennifer Ernst - Co-Founder, CEO & Director Lisa G. Wolf - CFO and Principal Financial & Principal Accounting Officer Operator Welcome to Tivic Health Systems Second Quarter 2025 Financial Results and Operational Update Conference Call.
Tivic Health Systems, Inc. (TIVC) Q2 2025 Earnings Call Transcript
Neutral
The Motley Fool
1 month ago
Tivic Health (TIVC) Q2 2025 Earnings Transcript
Image source: The Motley Fool.
Tivic Health (TIVC) Q2 2025 Earnings Transcript
Neutral
Business Wire
1 month ago
Tivic Reports Second Quarter 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. “We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems,” stated Tivic CEO Jennifer Ernst. “To maximize our focus o.
Tivic Reports Second Quarter 2025 Financial Results
Neutral
Business Wire
1 month ago
Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced that it will report its second quarter results for 2025 via pre-recorded conference call and webcast on Thursday, August 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 793820 Webcast Link https://www.we.
Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast
Neutral
Business Wire
2 months ago
Tivic Shareholders Approve Key Proposals in Support of Strategic Transformation; Lisa Wolf Appointed Permanent CFO
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that key proposals needed to carry out the company's strategic transformation were approved by shareholders at its annual meeting held on June 30, 2025. The approved proposals included the issuance of equity as a form of payment pursuant to Tivic's worldwide exclusive license agreement for Entolimod™ and Entolasta™, including for uses in acute radiation syndrom.
Tivic Shareholders Approve Key Proposals in Support of Strategic Transformation; Lisa Wolf Appointed Permanent CFO
Neutral
Business Wire
2 months ago
Tivic Health Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced it has completed all study visits in the Optimization Study for its patent pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Initial findings reinforce the importance of personalization for therapeutic efficacy. Tivic expects to release the study results later this year.
Tivic Health Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device
Neutral
Business Wire
2 months ago
Tivic Health Announces 2025 Annual Meeting of Stockholders
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today its Virtual Annual General Meeting of Shareholders will be held on Monday, June 30, 2025 at 1:00 PM, Pacific Time | 4:00 PM Eastern Time. The Company has adopted a virtual format for its Annual Meeting to provide a consistent and convenient experience for all stockholders regardless of their location. In lieu of a live Q&A session, stockholders can submit questio.
Tivic Health Announces 2025 Annual Meeting of Stockholders
Charts implemented using Lightweight Charts™